The final clinical trials of the new AstraZeneca anti-Coronavirus drug, AZD7442, showed its strong efficiency in the long term, Al Ain reported on Friday.
One 300 mg dose succeeded in reducing the risk of developing COVID-19 fatal symptoms by 83%, in addition, no severe COVID-19 related infections were recorded among the 73% of the participants when they faced high-risk infection conditions.
In the same context, another trial was dedicated to testing the impact of the new drug for mild and moderate symptoms.
It shows that the 600 mg dose could reduce the development of those symptoms by 88%
He added: “Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination.”
The leading drug manufacturer is expected to submit the latest results for the US Food and Drug Authority (FDA).